# Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer

> **NCT05784974** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 37 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Cadonilimab

## Key facts

- **NCT ID:** NCT05784974
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05784974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05784974, "Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05784974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*